Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

Similar articles for PubMed (Select 16705109)

1.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V.

JAMA. 2006 May 17;295(19):2275-85. Review. Erratum in: JAMA. 2006 Jun 7;295(21):2482.

PMID:
16705109
2.

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Salliot C, Dougados M, Gossec L.

Ann Rheum Dis. 2009 Jan;68(1):25-32. doi: 10.1136/ard.2007.083188. Epub 2008 Jan 18. Review.

3.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

5.

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A.

JAMA. 2011 Aug 24;306(8):864-71. doi: 10.1001/jama.2011.1211.

PMID:
21862748
6.
7.

The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.

Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK.

Am J Med. 2014 Dec;127(12):1208-32. doi: 10.1016/j.amjmed.2014.06.012. Epub 2014 Jun 17.

PMID:
24950486
8.

Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses.

Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M.

PLoS One. 2012;7(11):e48991. doi: 10.1371/journal.pone.0048991. Epub 2012 Nov 14.

9.
10.

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.

Leombruno JP, Einarson TR, Keystone EC.

Ann Rheum Dis. 2009 Jul;68(7):1136-45. doi: 10.1136/ard.2008.091025. Epub 2008 Aug 27. Review.

PMID:
18753157
11.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.

Health Technol Assess. 2011 Mar;15(14):1-278. doi: 10.3310/hta15140. Review.

12.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

13.

Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794. doi: 10.1002/14651858.CD008794.pub2. Review.

PMID:
21328309
14.

Adalimumab for treating rheumatoid arthritis.

Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005113. Review.

PMID:
16034967
15.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

PMID:
19224750
16.

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF.

Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. doi: 10.1016/j.cgh.2008.03.014.

PMID:
18550004
17.
18.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

19.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
20.

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A.

BMC Musculoskelet Disord. 2008 Apr 17;9:52. doi: 10.1186/1471-2474-9-52. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk